Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 579.8% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 133,828 shares of the biopharmaceutical company’s stock after buying an additional 114,143 shares during the period. SG Americas Securities LLC owned 0.13% of Alnylam Pharmaceuticals worth $12,506,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. ETF Managers Group LLC raised its holdings in Alnylam Pharmaceuticals by 15.7% during the fourth quarter. ETF Managers Group LLC now owns 1,086 shares of the biopharmaceutical company’s stock worth $79,000 after purchasing an additional 147 shares in the last quarter. Advisors Asset Management Inc. grew its position in Alnylam Pharmaceuticals by 0.9% during the fourth quarter. Advisors Asset Management Inc. now owns 17,883 shares of the biopharmaceutical company’s stock worth $1,304,000 after buying an additional 155 shares during the period. M&T Bank Corp grew its position in Alnylam Pharmaceuticals by 3.7% during the fourth quarter. M&T Bank Corp now owns 5,305 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 188 shares during the period. FUKOKU MUTUAL LIFE INSURANCE Co grew its position in Alnylam Pharmaceuticals by 40.0% during the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 700 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 200 shares during the period. Finally, Meeder Asset Management Inc. grew its position in Alnylam Pharmaceuticals by 332.9% during the first quarter. Meeder Asset Management Inc. now owns 342 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 263 shares during the period. 87.89% of the stock is owned by institutional investors and hedge funds.

In related news, CEO John Maraganore sold 49,457 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $70.00, for a total value of $3,461,990.00. Following the sale, the chief executive officer now directly owns 239,450 shares in the company, valued at approximately $16,761,500. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Philip A. Sharp sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $88.23, for a total transaction of $1,323,450.00. Following the completion of the sale, the director now owns 250,633 shares in the company, valued at $22,113,349.59. The disclosure for this sale can be found here. Insiders own 3.60% of the company’s stock.

ALNY has been the topic of several recent analyst reports. Morgan Stanley upgraded shares of Alnylam Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $122.00 target price on the stock in a research report on Tuesday, March 5th. ValuEngine lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 5th. UBS Group began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 23rd. They issued a “neutral” rating and a $87.00 price target on the stock. Evercore ISI began coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, April 11th. They issued an “outperform” rating and a $120.00 price target on the stock. Finally, BMO Capital Markets increased their price target on shares of Alnylam Pharmaceuticals from $126.00 to $128.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the stock. Alnylam Pharmaceuticals has a consensus rating of “Buy” and an average price target of $130.24.

ALNY stock traded down $0.06 during mid-day trading on Wednesday, hitting $67.81. 472,162 shares of the company were exchanged, compared to its average volume of 939,838. The firm has a market cap of $7.22 billion, a P/E ratio of -8.96 and a beta of 2.53. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.33 and a quick ratio of 9.12. Alnylam Pharmaceuticals, Inc. has a twelve month low of $60.27 and a twelve month high of $124.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.20) by $0.47. The company had revenue of $33.29 million during the quarter, compared to analyst estimates of $21.60 million. Alnylam Pharmaceuticals had a negative net margin of 929.51% and a negative return on equity of 55.33%. The firm’s revenue for the quarter was up 52.0% compared to the same quarter last year. During the same period last year, the business earned ($1.22) EPS. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -8.48 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was published by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://sundanceherald.com/2019/05/22/sg-americas-securities-llc-has-12-51-million-stake-in-alnylam-pharmaceuticals-inc-alny.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Article: Cost of Goods Sold (COGS)

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply